The medium-term management plan, “MTP2025,” is the plan for the initial five years to achieve Santen 2030. We have placed importance on these five years so we can focus our energy to maximize the value of our core businesses, and concurrently therewith, proceed with entering into new categories of business going forward to growth in 2026 and beyond.
We will utilize our strength as a global ophthalmic company cultivated through Vision 2020, our existing pipeline and assets, as well as our bases of business located in various places around the world with its center in Japan, realize steady growth in sales and profit and increase our earning power. In addition, through our full-scale entry into the business of prescription pharmaceuticals in the U.S., we aim for global growth in the medium-term. In parallel, while making the most of organizational capacity that has been cultivated until now as a specialty company in the ophthalmologic area, we aim to achieve the medium- and long-term growth set forth in Santen 2030 through investment for novel innovation, entry to novel business fields such as cellular therapy, as well as capital investment (including investment to factories) and the like. Through this, we will steadily execute strategic policies towards transformation into a Social Innovator.
*Rx: prescription pharmaceuticals
|TSR*||Top 1/2 level in pharma industry|
|Net sales||≥ 315 billion yen (CAGR 5%)|
|Operating profit ratio (IFRS)||≥ 21%|
|Overseas sales ratio||≥ 50%|
|Shareholder return||≥ 40% in payout ratio + Opportunistic share buy-back(s)|
|Jun 05, 2018|
|Aug 06, 2014|
|May 11, 2011|
|Jul 25, 2006|
|Feb 20, 2003|